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During organogenesis, tissues expand in size and eventually acquire consistent ratios of cells with
dazzling diversity in morphology and function. During this process progenitor cells exit the cell cycle
and execute differentiation programs through extensive genetic reprogramming that involves the
silencing of proliferation genes and the activation of differentiation genes in a step-wise temporal
manner. Recent years have witnessed expansion in our understanding of the epigenetic mechanisms
that contribute to cellular differentiation and maturation during organ development, as this is a crucial
step toward advancing regenerative therapy research for many intractable disorders. Among such
epigenetic programs, the developmental roles of the polycomb repressive complex 2 (PRC2), a
chromatin remodeling complex that mediates silencing of gene expression, have been under intensive
examination. This review summarizes recent ﬁndings of how PRC2 functions to regulate the transition
from proliferation to differentiation during organogenesis and discusses some aspects of the remaining
questions associated with its regulation and mechanisms of action.
& 2012 Elsevier Inc. All rights reserved.Chromatin remodeling and gene regulation
During embryonic development, the process of organogenesis
requires that multipotent progenitor cells respond to developmen-
tal cues that drive speciﬁc cell fate decisions. These developmental
events are orchestrated through signiﬁcant changes in gene
expression that ultimately execute programs of cellular differentia-
tion and maturation. One powerful means of regulating gene
expression during development is through control of chromatin
structure, which determines accessibility to DNA. Changes in the
structure of chromatin are governed in part by post-translational
modiﬁcations (PTMs) of histones, processes that are mediated by
complexes that bind and covalently modify the amino acid side
chains of histone tails that are exposed over the surface of the
nucleosome. Histone modiﬁcations are diverse in nature and
include acetylation of lysines, methylation of arginines and lysines,
and phosphorylation of serines and threonines, among others
(Berger, 2007). Mechanistically, a histone tail may simultaneously
harbor several modiﬁcations that collectively form a unique dock-
ing site that promotes the recruitment of distinct protein com-
plexes that subsequently affect chromatin structure and gene
expression (Berger, 2007; Turner, 2007).
The correlation between histone modiﬁcations and transcrip-
tion states has been the subject of focused investigation.ll rights reserved.
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positive- or negative-acting histone PTMs are established on gene
promoters which in turn can facilitate recruitment of activators or
repressors of gene expression, respectively (Berger, 2007). For
instance, trimethylation of lysine 4 in histone 3 (H3K4me3) is
enriched on the 50 end of open reading frames and correlates well
with transcription activation, and is thus considered an activating
mark (Berger, 2007; Chi et al., 2010; Turner, 2007). On the other
hand, enrichment in modiﬁcations such as H3K9me3 and
H3K27me3 is associated with silenced genes (Boyer et al., 2006;
Lee et al., 2006; Snowden et al., 2002). However, how well histone
PTMs can be predictive of the state of transcription remains
unclear. Nevertheless, it is increasingly clear that modulating
chromatin structure through histone modiﬁcation is an important
means of regulating the expression of large groups of develop-
mental and signaling genes, and that this is a central mechanism
for coordinating developmental transitions during organogenesis.
One important class of chromatin modiﬁers are the Polycomb
group (PcG) genes, which encode highly conserved factors that
mediate gene silencing. They were initially identiﬁed in Droso-
phila as repressors of Hox genes during developmental patterning
(Alexander et al., 2009; Sparmann and van Lohuizen, 2006).
Mutations of PcG members in Drosophila embryos disrupt the
correct spatial and temporal expression pattern of Hox genes in
body segmentation, leading to embryonic posteriorization
(Ringrose and Paro, 2004). This function is also conserved in
vertebrates where mutations in several polycomb factors lead to
skeletal malformations as a result of disruption of Hox gene
expression (Akasaka et al., 1996; del Mar Lorente et al., 2000).
Fig. 1. The polycomb complex PRC2 functions as a histone methyltransferase.
PRC2 contains four core components: EZH1/2, SUZ12, EED and RbBP4/7. PRC2
recruitment to gene promoters leads to deposition of H3K27me3, which is
associated with gene repression.
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still under intensive study. Several biochemically and functionally
distinct complexes, termed Polycomb Repressive Complexes (PRCs),
have been puriﬁed including, PRC1 and PRC2 (Akizu et al., 2010;
Martinez and Cavalli, 2006). PRC1 catalyzes the monoubiquitylation
of lysine 119 of histone H2A (H2A119ub) while PRC2 has methyl-
transferase activities and is primarily responsible for histone3 lysine
27 di-/tri-methylation (H3K27me2/3) (Fig. 1) (Kuzmichev et al.,
2002; Sawarkar and Paro, 2010). Interestingly, PRC1 binds the PRC2-
mediated mark H3K27me3, and shares occupancy with many of its
target genes, providing a functional link between both complexes
(Fischle et al., 2003). The addition of H3K27me3 by PRC2 has been
proposed to facilitate gene repression by recruiting PRC1 to the
methylated region (Cao et al., 2005; Spivakov and Fisher, 2007).
However this particular recruitment order (PRC2 then PRC1) has not
been ﬁrmly established (Margueron and Reinberg, 2011), and there
is also evidence that PRC1 and PRC2 do not always occupy the same
genomic loci (Ku et al., 2008). Notably, in embryonic stem (ES) cells,
PRC1 and PRC2 act redundantly to regulate the ability of these cells
to differentiate, since they both repress common developmental
regulators, and both PRC1 and PRC2 must be eliminated to prevent
ES cell differentiation (Leeb et al., 2010). Thus it is likely that PRC1
and PRC2 have overlapping as well as distinct roles (Richly et al.,
2011; Simon and Kingston, 2009).
PcGs can mediate silencing of a broad range of genes, and are
associated with important biological contexts such as mainte-
nance and differentiation of ES cells, as well as cancer progression
(Boyer et al., 2006; Lee et al., 2006; Schwartz et al., 2006). While
much has been learned about the biochemical roles of PcGs
(Margueron and Reinberg, 2011; Simon and Kingston, 2009), only
recently are we gaining an appreciation for their fundamental
roles as developmental regulators. While both PRC1 and PRC2
likely function to regulate key aspects of development, recently
there has been a particular focus on PRC2, with increasing
evidence that this complex plays a critical role in regulating
differentiation decisions during vertebrate embryogenesis. Thus,
in this review we speciﬁcally highlight what is known about the
developmental roles of PRC2 function during tissue development.The polycomb repressive complex PRC2
PRC2 consists of four core subunits: SUZ12 (the mammalian
orthologue of Suppressor of Zeste Su(z) 12), EZH2 (the mamma-
lian orthologue of Enhancer of Zeste (E(z)), EED (the mammalianorthologue of Extra Sex Combs ESC) and Retinoblastoma
Associated Protein RbAP46/48 (also known as RbBP4/7; the
mammalian orthologue of P55) (Fig. 1) (Kuzmichev et al., 2002;
Margueron and Reinberg, 2011). These components encompass a
diverse cohort of functional activities. SUZ12, for instance, contains
a zinc ﬁnger motif and is required for EZH2 catalytic activities
(Pasini et al., 2004). EZH2 bears histone methyltransferase activity
through its highly conserved SET domain: mutations in the SET
domain cause loss of H3K27me3 in Drosophila as well as in
vertebrates (Kuzmichev et al., 2002; Muller et al., 2002; Su et al.,
2003). Interestingly, recent studies have identiﬁed a version of
PRC2 that contains the EZH2 homolog, EZH1, which can also
mediate trimethylation of H3K27 (Margueron et al., 2008; Shen
et al., 2008). The third component, EED, is a WD-40 repeat protein
that interacts with EZH2 and is required for the EZH2 methyl-
transferase activity (Ketel et al., 2005; Kuzmichev et al., 2005). EED
also plays an important role in the maintenance and propagation of
H3K27me3 during cell division since it binds H3K27me3 through
its C-terminal domain (Margueron et al., 2009). Together, EZH2,
EED and SUZ12 constitute the minimal PRC2 subunits required for
catalytic activity and subsequent initiation of gene repression
(Ketel et al., 2005; Sparmann and van Lohuizen, 2006). The fourth
core component, RbBP4/7, is required for association of PRC2 with
the histone tail (Kuzmichev et al., 2002).
Beside the core subunits, PRC2 contains other factors such as
JARID2, AEBP2, and PCL that have been shown to occupy most
PRC2 target genes (Margueron and Reinberg, 2011; Nekrasov et al.,
2007; Peng et al., 2009; Shen et al., 2009). The exact function of
these components is not well understood, but evidence suggests
that while they are not essential for PRC2-mediated catalytic
function per se, their presence modulates PRC2 enzymatic activ-
ities and promotes DNA binding (Margueron and Reinberg, 2011).Roles of PRC2 in differentiation and cell fate commitment
Invertebrate studies support the concept that PcGs play
important roles as regulators of developmental gene expression,
but only recently is a detailed picture emerging for vertebrate
models (Fig. 2). In mouse, mutants of Suz12, Ezh2 and Eed display
developmental and proliferative abnormalities and are lethal at
early postimplantation stages (Faust et al., 1998; O’Carroll et al.,
2001; Pasini et al., 2004). Although these mutations demonstrate
how essential PRC2 is for vertebrate development, they shed no
light on the tissue-speciﬁc roles that PRC2 might play in differ-
entiation and cell fate acquisition.
Important insights into the roles of PRC2 in development came
from studies on ES cells. Recent excellent reviews have covered
this topic (Surface et al., 2010) and we shall only discuss it brieﬂy.
Genome wide analysis of PRC2 targets in ES cells revealed that
PRC2 and its mark H3K27me3 occupy inactive promoters of key
developmental regulators, suggesting a role in the maintenance of
ES cell pluripotency (Boyer et al., 2006; Lee et al., 2006). However,
this role has been questioned in more recent studies (Chamberlain
et al., 2008; Shen et al., 2008; Surface et al., 2010). For example, ES
cells can be established from PRC2 core subunit mutants, and, in
the case of the Eed mutant, they contribute robustly to multiple
lineages in vivo, suggesting that PRC2 is not strictly required for
pluripotency (Chamberlain et al., 2008; Pasini et al., 2007; Shen
et al., 2008). Rather, PRC2 has a prominent role in the proper
differentiation of ES cells since ES cells lacking PRC2 components
fail to differentiate in culture conditions (Pasini et al., 2007; Pietersen
and van Lohuizen, 2008; Shen et al., 2008). These ﬁndings have
led to consideration of PRC2 as a regulator of cellular transitions
and differentiation decisions.
Fig. 2. Roles of PRC2 during tissue differentiation: (A) schematic ﬁgure showing major developmental transitions at which PRC2 functions, including (I) multipotent cell
identity, (II) lineage commitment, (III) progenitor expansion, (IV) differentiation/cell fate choice. (B) Reported tissues that are under regulation by PRC2 during
development. Roman numbers represent steps from panel A that have been shown to be regulated by PRC2 while numbers refer to related citations on the reference list to
the right. See text for details.
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in ES cells many of the genes involved in differentiation are
co-occupied by the repressive mark H3K27me3 and the activating
mark H3K4me3, forming a unique status of ‘‘bivalent domain’’
(Bernstein et al., 2006). Upon differentiation, PRC2 occupancy is
lost and H3K27me3 is removed while H3K4me3 is maintained,
permitting expression of differentiation genes (Boyer et al., 2006;
Lee et al., 2006). Thus the PRC2-mediated repression of the
developmental gene promoters occupied with the bivalent domain
is transient and seems to prime ES cells for subsequent lineage
commitment and cell fate decisions (Landeira et al., 2010; Pietersen
and van Lohuizen, 2008; Surface et al., 2010). Recently, it has been
shown that the presence of H3K4me3 allosterically inhibits PRC2
catalytic function, raising interesting questions about how bivalent
domains are established in ES cells (Schmitges et al., 2011).
In principle, if PRC2 regulates aspects of embryonic stem cell
proliferation and differentiation, it may also do so during organ
development. The discovery that H3K27me3 can be actively removed
by speciﬁc demethylases has further potentiated interest in the
involvement of PRC2 during tissue development because such
function implies that this mark can be transiently utilized to control
gene expression, and thus has the potential to play important roles in
organogenesis (Lan et al., 2007). If tissue differentiation is executed
according to an ES cell culture differentiation paradigm, this predicts
that tissue-speciﬁc inactivation of PRC2 core components during
organogenesis should lead to suppression of differentiation and cell
fate acquisition (Margueron and Reinberg, 2011). However, observed
outcomes from studying the effect of PRC2 mutations on tissue
development suggest that PRC2 function is context-speciﬁc and
depends on selective targeting of gene expression. What is clear is
that PRC2 functions to regulate cellular transitions during develop-
ment, acting to either promote or block differentiation, to ﬁne-tune
cell fate acquisition and/or to preserve proper cell identity during
progression from proliferation to differentiation (Fig. 2).
Consistent with what has been observed in ES cells, in some
contexts PRC2 is required for tissue differentiation. For example, a
mouse mutation in Eed causes a partial block in thymocyte differ-
entiation, and inactivation of Ezh2 in adipose tissue impairs adipocyte
differentiation due to an abnormal activation of canonical Wntsignaling, a major inhibitor of adipogenesis (Richie et al., 2002;
Wang et al., 2010). In contrast, in some contexts PRC2 is required
to constrain differentiation. For instance, inhibition of Ezh2 function in
mouse epidermal progenitors results in accelerated skin development
likely as the result of precocious recruitment of the transcription
factor AP-l, which directs a late epidermal differentiation pro-
gram, to terminal differentiation gene promoters (Ezhkova et al.,
2009; Pirrotta, 2009). Similarly, loss of Ezh2 enhances hepatogen-
esis and accelerates hepatic maturation in cultured uncommitted
hepatic cells although the mechanism is poorly understood (Aoki
et al., 2010). Moreover, knockdown of Suz12 in intestinal epithe-
lial cells results in a precocious differentiation due to selective
upregulation of terminal differentiation genes (Benoit et al., 2012).
Together these ﬁndings reveal more complexity than initially
apparent from ES cell studies, which do not recapitulate the spatial
and temporal aspects of in vivo tissue development, nor the
inﬂuence of environmental factors or tissue interactions.
Analysis of PRC2 function at multiple stages of development
within a given tissue demonstrates additional complexity to PRC2
function. For example, during limb development, Ezh2 is required at
early stages for establishing the limb anterior–posterior axis, while
at later stages it is required for cell survival and digit elongation, in
part through changes in the regulation of Hox gene expression
(Wyngaarden et al., 2011). Importantly, the authors found that
during late limb bud stages Ezh2 is required for cells to switch from
plasticity to a determined state, since Ezh2mutant but not wild type
cells could be respeciﬁed in the presence of new positional cues
(Wyngaarden et al., 2011). This parallels work in Caenorhabditis
elegans embryos showing that the Polycomb complex protein MES-
2/E(Z) is required for transition from a developmentally plastic state
to the onset of differentiation (Yuzyuk et al., 2009).
There is also evidence that in some contexts PRC2 prevents
inappropriate expression of genes from alternate lineages. For exam-
ple, Ezh2 knockouts cause heart defects as a result of a disruption of
normal gene expression proﬁle in cardiomyoctes, including an
upregulation of noncardiomyocyte genes, such as Six1, which
promotes activation of skeletal muscle genes in differentiating
cardiac muscle (Chen et al., 2012; Delgado-Olguin et al., 2012; He
et al., 2011). Ezh2 also regulates terminal cell fate choices during
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sing the pancreatic cell fate gene Pdx1 to allow cells to adopt a
liver cell fate (Xu et al., 2011). Together these data underscore the
importance of in vivo analysis in diverse lineages for deﬁning the
role of PRC2 in differentiation decisions.
In many tissues a marked reduction in cell proliferation is also
observed upon loss of Ezh2, in part due to an abnormal upregula-
tion of the tumor suppressor gene p16(Ink4A), a major target for
PRC2 repression (Aoki et al., 2010; Chen et al., 2009; Ezhkova
et al., 2009; He et al., 2011; Juan et al., 2011). This suggests an
additional role of PRC2 in controlling the balance between
proliferation and differentiation and is consistent with data from
cancer studies where upregulation of Ezh2 has been linked to
different types of malignancies, and thus used as a marker for
several types of aggressive tumors (Fullgrabe et al., 2011; Kleer
et al., 2003; Varambally et al., 2002). For instance, Ezh2 is highly
expressed in certain types of gliomas and in glioma stem-like
cells, and is required for glioma cell proliferation (Orzan et al.,
2011). Interestingly, recent studies reported recurrent somatic
mutations in lysine 27 of histone variants H3.3 and H3.1 in
pediatric brain gliomas, further underscoring the importance of
epigenetic mechanisms in the regulation of cancer malignancies
and providing potential avenues for diagnosis and treatment of
cancer (Schwartzentruber et al., 2012; Wu et al., 2012).The roles of PRC2 and H3K27me3 during myogenesis
The magnitude of the complexity of PRC2 function during
organogenesis can be demonstrated by brieﬂy considering its multi-
ple stage-speciﬁc roles during skeletal muscle differentiation. Ezh2
was initially found to be expressed in dividing myoblasts of the
mouse embryo. In ﬁbroblast reporter assays, Ezh2 could inhibit the
activation of transcription mediated by the myogenic factor MYOD,
and in undifferentiated cultured myoblasts it was required to restrict
the expression of muscle differentiation genes, suggesting that PRC2
is necessary to prevent premature differentiation (Caretti et al.,
2004; Prezioso and Orlando, 2011). However, myoblast differentia-
tion proceeded normally upon Ezh2 knockdown in cell cultures, and
Ezh2 conditional knockout in mice produced no obvious muscle
defects during embryonic development (Juan et al., 2011; Stojic
et al., 2011). Rather, Ezh2 seems to be required for postnatal muscle
growth and regeneration, acting to maintain identity of postnatal
muscle stem cells by constraining the expression of genes irrelevant
to muscle development rather than suppressing muscle-speciﬁc
transcription (Juan et al., 2011). It seems that Ezh1, which is
expressed in differentiating myoblasts, plays a more prominent
role during embryonic muscle development in the progression
from proliferation to differentiation. Upon knockdown of Ezh1,
but not Ezh2, cultured myoblasts failed to differentiate properly
and exhibited a delay in expression of the muscle-speciﬁc bHLH
gene myogenin due to reduced recruitment of MYOD to the
myogenin promoter (Stojic et al., 2011). This example highlights
how the composition of PRC2 subunits can be an important factor
in the regulation of multiple steps in the differentiation process.
The roles of PRC2 and H3K27me3 during neurogenesis
The ﬁrst glimpse of possible functions of PRC2 in neural differ-
entiation came from ES cell studies where it was shown that many of
the genes involved in neurogenesis are targets for PRC2-mediated
deposition of H3K27me3 (Boyer et al., 2006; Lee et al., 2006).
However, ES cells lacking Suz12 do not overproduce neurons but
rather suffer a failure in executing a proper neural differentiation
program under differentiation conditions, presumably due to loss of
H3K27me3 (Pasini et al., 2007). Interestingly, sustained maintenanceof H3K27me3 by knocking down the H3K27me3-speciﬁc demethy-
lase Jmjd3 is also detrimental to ES cell neural differentiation, further
suggesting that transient H3K27me3 deposition is essential for the
proper execution of the neural differentiation program (Burgold
et al., 2008; Sen et al., 2008).
In agreement with data from non-neural tissue development,
the function of PRC2 during neural development is context-
dependent and does not necessarily follow the ES cell differen-
tiation model. For instance, in mammalian neocortex, either
shRNA-mediated knockdown of Eed, or tamoxifen-induced Ezh2
conditional inactivation in neural precursor cells in culture caused
a delay in the switch in neural precursor cells from generating
neurons to astrocytes, resulting in increased production of neurons
(Hirabayashi et al., 2009). Tamoxifen-induced disruption of Ezh2
in vivo during the neurogenic period under the control of ERT2-Cre
had a similar effect by extending the neurogenic phase in the
developing cortex. In this tissue PRC2 cooperates with PRC1 to
restrict the ability of neural progenitors to generate neurons by
repressing expression of the proneural bHLH factor neurogenin
(Ngn1) during the late phase of neocortical development when the
time is proper for astrocyte production (Hirabayashi and Gotoh,
2010; Hirabayashi et al., 2009). In a separate study, conditional
inactivation of Ezh2 using Emx1-Cre, which inactivates Ezh2 before
the onset of neurogenesis, results in a shift from self-renewal
towards differentiation, and accelerates the developmental timing
for both cortical neurogenesis and gliogenesis (Pereira et al., 2010).
This is in contrast to extension of the neurogenic period and delay
of gliogenesis reported by Hirabayashi and colleagues (Hirabayashi
et al., 2009). The differences in these ﬁndings could be due to
differences in Cre drivers and timing of inactivation, which
warrants further investigation (Testa, 2011). Nevertheless, these
studies reinforce the general concept that in many contexts PRC2
functions to regulate the timing of developmental transitions.
Interestingly, PRC1 and PRC2 appear to play similar roles in
regulating neocortical development, since tamoxifen-induced inac-
tivation of the PRC1 component Ring1b in neural progenitors in vivo
using ERT2-Cre phenocopies the Ezh2 mutant (Hirabayashi and
Gotoh, 2010; Hirabayashi et al., 2009). However, there are likely
additional functions for PRC1 components since the PRC1 compo-
nent Bmi-1 is required for neural stem cell self-renewal, in part
through repression of the cell cycle inhibitors p16, p19, and p21
(Fasano et al., 2007; Molofsky et al., 2005, 2003). Analysis of
PRC1/PRC2 double mutants will be important for assessing the
degree of functional overlap for these complexes during neural
development.
There are additional potential roles for Ezh2 in the developing
nervous system. In neurosphere culture of cells isolated from the
mouse telencephalon at E14, Ezh2 controls the cell fate choice
between oligodendrocytes and astrocytes, with downregulation of
Ezh2 expression being required to promote the production of
astrocytes (Fasano et al., 2007; Sher et al., 2008). Whether Ezh2
plays a role in the development of oligodendrocytes in vivo remains
to be determined. In the chick spinal cord, EZH2 activity is not
required for neuroblast proliferation or for neural differentiation, but
is required for dorsoventral patterning through regulation of Noggin
expression and dorsal BMP signaling (Akizu et al., 2010). This is
consistent with previously described roles for PRC2 in consolidating
positional identity of progenitors in development (Sparmann and
van Lohuizen, 2006). Additionally, there is preliminary evidence that
PRC2 may be involved in the regulation of neural crest cells. PRC2
components are expressed in neural crest derivatives, and the PRC2
binding partner Aebp2 is required for mouse neural crest derivatives
(Aldiri and Vetter, 2009; Kim et al., 2011).
In general, the role of PRC2 in the development of various
tissues is complex, and likely to be stage-speciﬁc. Nevertheless, a
clear picture emerges of PRC2 as a regulator of developmental
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tally plastic progenitors to lineage committed precursors and
ultimately terminally differentiated cells. During this process
PRC2 can act to either promote or block these transitions, and
can also consolidate or preserve proper cell identity (Fig. 2).Complementary roles of Ezh1 and Ezh2 during development
EZH1 and EZH2 are partially redundant in establishing H3K27me3
and can occupy similar target genes, and in some cases have been
proposed to play redundant roles. In ES cells, Ezh1 is required for
differentiation and for repression of developmental genes, similar to
Ezh2 (Margueron et al., 2008; Shen et al., 2008). In skin, both Ezh1 and
Ezh2 are expressed, and target similar epidermal differentiation genes
(Ezhkova et al., 2009). Furthermore, disruption of Ezh2 results in an
incomplete loss of H2K27me3 in skin, suggesting compensation by
Ezh1. Ezh1 is dispensable for epidermal differentiation during devel-
opment, however double inactivation of Ezh1 and Ezh2 leads to arrest
in hair follicle morphogenesis and impairs skin regeneration in
postnatal mice demonstrating functional redundancy in this tissue
(Ezhkova et al., 2011).
Nevertheless, it is also clear that the developmental roles of
Ezh1 and Ezh2 can also be distinct and context dependent. During
organogenesis in many tissues Ezh2 expression is mainly conﬁned
to embryonic tissues while Ezh1 persists postnatally (Ezhkova
et al., 2009; Margueron et al., 2008). Meanwhile, Ezh1, but not
Ezh2, is required for myoblast differentiation in mouse, and Ezh1
regulates left–right asymmetry in medaka through silencing of
Nodal (Arai et al., 2010; Stojic et al., 2011). These data highlight
the importance of studying the consequences of inactivation Ezh1
alone or in combination with Ezh2 to dissect the contribution of
these enzymes to organ formation. Additionally, if Ezh1 can truly
compensate for the absence of Ezh2, as many studies have
proposed, then knocking Ezh1 into the Ezh2 locus in mice should
restore organ defects observed upon loss of Ezh2. Such experi-
ments might be necessary to reveal the extent to which EZH1 and
EZH2 can act redundantly during organogenesis.H3K27me3 deposition during development
Understanding the mechanism by which PRC2 regulates pro-
gression from proliferation to differentiation has relied heavily on
identifying target genes occupied by H3K27me3 and characteriz-
ing the pattern of this mark during development using chromatin
immunoprecipitation coupled with microarray analysis (ChIP–chip)
and ChIP-sequencing analyses. It has been found that H3K27me3
deposition is dynamic and particularly selective in a tissue-speciﬁc
manner during organogenesis. For example H3K27me3 mark is
enriched on the promoter of the bHLH factor Ngn1 to suppress
neurogenesis as progenitors transition to the generation of astro-
cytes in the developing neocortex (Hirabayashi et al., 2009).
Conversely, H3K27me3 deposition contributes to postnatal olfac-
tory bulb neurogenesis by repressing the expression of the
neurogenic gene Dlx2 in neural stem cells residing in the sub-
ventricular zone (SVZ), thus preserving their potential to produce
astrocytes and oligodendrocytes (Lim et al., 2009). In addition,
during skin development H3K27me3 occupancy is maintained on
terminal differentiation genes in basal epidermal cells and is
progressively lost as development proceeds toward terminal
differentiation (Ezhkova et al., 2009). These examples underscore
how a single molecular mechanism can be utilized in a tissue- and
stage-speciﬁc manner to achieve differential roles during the
progression from proliferation to differentiation and ﬁnal fate
acquisition in organ development.Notably, H3K27me3 enrichment is not limited only to tissue-
speciﬁc genes during organogenesis, suggesting that PRC2 loss of
function may cause a global de-repression of genes associated
with multiple lineages, as was observed in ES cells (Boyer et al.,
2006; Lee et al., 2006). However, inactivation of PRC2 in vivo leads
to upregulation of only a minority of those genes, and the overall
effect of PRC2 conditional mutants on organ development is
relatively mild (Ezhkova et al., 2009; He et al., 2011; Hirabayashi
et al., 2009; Wyngaarden et al., 2011). Hence, it is unlikely that the
H3K27me3-mediated repression is the sole mechanism that acts
to constrain gene expression during organ formation.
In principle, the expression of PRC2 subunits and its mark
H3K27me3 should extensively overlap during tissue development.
Paradoxically, in several tissues while Ezh2 is mainly enriched in
dividing cells, the global level of the H3K27me3 mark is maintained
or increased concomitant with differentiation, including in mouse
retina, heart, limb, skin and chick spinal cord (Akizu et al., 2010;
Ezhkova et al., 2009; He et al., 2011; Rao et al., 2010; Wyngaarden
et al., 2011). The apparent inverse correlation between the expression
of Ezh2 and H3K27me3 deposition is counterintuitive, however,
studies have revealed that the EZH2 homolog, EZH1, can be respon-
sible for the addition of the H3K27me3 in differentiating cells (Akizu
et al., 2010; Ezhkova et al., 2009; Margueron et al., 2008; Stojic et al.,
2011). Since the catalytic function of EZH1 also requires the presence
of the core subunits SUZ12 and EED, it will be important to
characterize the expression of these components after the initiation
of differentiation in detail. Indeed, a recent study has shown that
while the protein levels of EZH2 diminish with differentiation, EED
and SUZ12 are maintained, albeit at low levels, and in association
with EZH1 are required for myoblast differentiation (Stojic et al.,
2011). The biological signiﬁcance of the presence of PRC2 complexes
that contain EZH1 instead of the canonical EZH2 is poorly understood,
but may reﬂect a potential role in target selectivity (Ho and Crabtree,
2008; Margueron et al., 2008; Stojic et al., 2011). Similarly, why
H3K27me3 is enriched in fully differentiated cells remains unclear,
but it is possible that it is used to stabilize terminal cell fate decisions
by permanently suppressing the expression of all genes that are not
related to the maintenance of the fully differentiated cells.
Given that H3K27me3 occupancy can be transient during
differentiation, it is unclear how H3K27me3 is removed during
this process. Histone demethylases are important class of chro-
matin remodeling factors and have increasingly been found to
have essential functions during development and diseases
(reviewed in Pedersen and Helin, 2010). H3K27me3 speciﬁc
demethylases, UTX and JMJD3, have been identiﬁed and impli-
cated in neural commitment and the differentiation of muscle and
skin in culture (Burgold et al., 2008; Lan et al., 2007; Seenundun
et al., 2010; Sen et al., 2008). Recently, in vivo analysis has
demonstrated that UTX is essential for heart development, and
acts as a developmental switch in the cardiac lineage to induce
expression of cardiac genes in association with core cardiac
transcription factors (Lee et al., 2012). Since UTX is broadly
expressed there is much to be learned about the roles of
H3K27me3 demethylases, and how their functions are coordi-
nated with PRC2 activities during embryonic development.Regulation of PRC2 function during development
Regulation of PRC2 subunit expression
The enrichment of PRC2 core subunit expression in proliferating
cells suggests the presence of a regulatory mechanism that tightly
controls the induction/maintenance of PRC2 transcription in pro-
genitors while shutting it off upon initiation of differentiation (Akizu
et al., 2010; Ezhkova et al., 2009; He et al., 2011; Stojic et al., 2011).
I. Aldiri, M.L. Vetter / Developmental Biology 367 (2012) 91–9996Given that the function of PRC2 is context-dependent, this mechan-
ism is likely to be tissue-speciﬁc as well. Additionally, since EZH1
and EZH2 show differential expression patterns, it is likely that these
two subunits are regulated by distinct mechanisms. We propose
that early transcription factors or signaling pathways that drive
tissue speciﬁcation and differentiationmay control PRC2 expression:
factors that control cell proliferation and self-renewal could be
involved in maintaining high expression of PRC2 components, while
factors that promote cellular differentiation could function to con-
strain PRC2 transcription as part of their differentiation program.
While there is no direct in vivo evidence to support this model,
information from tissue culture, ES cells, and cancer studies may
provide insight into possible mechanisms. For example, the micro-
RNA miR-214, which drives muscle speciﬁcation, is involved in a
negative feedback loop to inhibit the translation of Ezh2 in skeletal
muscle cells and ES cells (Juan et al., 2009). Further, it has been
shown that the transcription factor E2F induces the expression of
the PRC2 core subunits Eed and Ezh2 in tumor cells and in ﬁbroblasts
(Bracken et al., 2003; Muller et al., 2001). More recently, Myc family
members were found to be necessary and sufﬁcient to promote the
expression of PRC2 components in ES cells (Neri et al., 2011).
Whether any of these factors is part of the regulatory mechanism
governing PRC2 expression during organogenesis remains to be
tested.
Posttranslational modiﬁcations
There is mounting evidence that PRC2 proteins are targeted for
sumoylation and phosphorylation (Margueron and Reinberg,
2011; Riising et al., 2008). While the functional signiﬁcance of
sumoylation remains unclear, EZH2 phosphorylation has been
particularly studied, and been shown to modulate PRC2 binding
and catalytic activities in a site-dependent manner. While phos-
phorylation of particular sites inhibits catalytic activities and
interfere with EZH2 binding, other sites seem to promote EZH2
function (reviewed in Caretti et al., 2011; Chou et al., 2011). The
responsible kinases have been identiﬁed and shown to be the cell
cycle regulators CDK1 and CDK2 (Chen et al., 2010; Kaneko et al.,
2010; Zeng et al., 2011). Hence, regulation of EZH2 phosphoryla-
tion can provide an additional mechanism to modulate PRC2
activities in a spatial and temporal manner during the transition
from proliferation to differentiation. For example, the CDK1-
mediated phosphorylation of human EZH2 at Thr 487 inhibits
its catalytic function, promoting osteogenesis in mesenchymal
stem cells (Wei et al., 2011). EZH2 can also be phosphorylated by
AKT signaling, which opens the door for investigating the link
between environmental cues and regulation of PRC2 function
during organ formation (Cha et al., 2005). Further, whether EZH1
activity is subject to regulation by posttranslational modiﬁcation
in a similar manner to EZH2 remains to be fully explored.
Recruitment of PRC2
One of the least understood aspects of PRC2 function is how it
achieves target speciﬁcity during the transition state from pro-
liferation to differentiation. The core PRC2 binds DNA with low
afﬁnity, indicating the presence of a recruiting mechanism that
directs PRC2 to its intended targets. Additional PRC2 cofactors
such as JARID2 promote binding of PRC2 to the DNA (Landeira
et al., 2010; Li et al., 2010; Peng et al., 2009). However, since
JARID2 is a bona ﬁde partner of PRC2, it is still unclear why
recruitment is particularly selective (Landeira and Fisher, 2010;
Margueron and Reinberg, 2011). In principle, PRC2 recruitment
can be facilitated by the presence of unique DNA elements in the
targeted promoters. Indeed, such unique sequences, termed Poly-
comb Response Elements (PREs), have been previously identiﬁed inDrosophila and, to a certain extent, mouse and shown to bind PRC2
via association with PRC1 (Bracken and Helin, 2009; Sing et al.,
2009). More importantly, a model that suggests the involvement of
transcription factors in the regulation of PcG recruitment was
proposed (Bracken and Helin, 2009). According to this model,
factors that drive cell fate speciﬁcation can promote recruitment
or dissociation of PRC2 during differentiation in a tissue-speciﬁc
manner (Bracken and Helin, 2009). In support to this model, a
recent study elegantly demonstrates that the homeoprotein MSX1,
which regulates myoblast differentiation and limb formation,
physically interacts with EZH2 and forces it to relocalize to the
nuclear periphery (Wang et al., 2011). This relocalization of EZH2
leads to the redistribution of H3K27me3 to the nuclear lamina and
subsequent repression of MSX1 target genes in myoblasts. Hence,
we expect that performing tissue-speciﬁc pull-down experiments
may identify additional tissue-speciﬁc PRC2 binding partners.
However, it should be taken into consideration that the association
between PRC2 and these factors could be transient and depend
upon posttranslational modiﬁcations of PRC2 components (Palacios
et al., 2010; Singh and Dilworth, 2011).
Additionally, long non-coding RNAs (ncRNAs) have been
implicated in the recruitment of PRC2 (Bracken and Helin, 2009;
Margueron and Reinberg, 2011; Ng et al., 2012). For instance, the
ncRNA HOTAIR associates with PRC2 and promotes its recruitment
to HOXD locus for subsequent repression in trans (Rinn et al., 2007).
Several long ncRNAs have been identiﬁed and shown to have tissue-
speciﬁc expression, suggesting possible PRC2-dependent roles in
organogenesis (Pauli et al., 2011). For example, the lncRNA Six3OS is
speciﬁcally expressed in the developing retina and hypothalamus, is
involved in retinal cell fate decisions and interacts with Ezh2 as well
as Eya family members (Rapicavoli et al., 2011). Recently, Margueron
and Reinberg proposed a model stipulating that the collective step-
wise weak interactions of PRC2 core and auxiliary components with
histone, DNA, and H3K27me3, and its association with long ncRNA,
provides a sufﬁcient platform for PRC2 recruitment to its targets
(Margueron and Reinberg, 2011). Validating this model during
organogenesis awaits further experimentation.Perspectives and future directions
Recent years have witnessed tremendous progress in our
understanding of the contribution of PRC2 to differentiation and
cell fate speciﬁcation, yet much remains to be explored. We
expect that additional tissues will be added to the list of organs
regulated by PRC2, and more details about PRC2 mechanism of
action will be revealed. Most studies have focused on the roles of
nuclear PRC2 in catalyzing the addition of H3K27me3 and
repressing gene expression during organogenesis. However, the
full spectrum of PRC2 alternative roles has not been explored. For
instance, PRC2 can localize to the cytoplasm where it promotes
actin polymerization through its methyltransferase activities
(Bryant et al., 2008; Su et al., 2005). Regulation of actin poly-
merization is essential for proper cell morphogenesis during
organogenesis, suggesting that PRC2 might be involved in this
process. Strikingly, in breast cancer cells EZH2 binds the Wnt
effector b-catenin and promotes transcriptional activation of
genes under estrogen control, independent of its methyltransfer-
ase activities, and in the absence of other PRC2 core subunits
(Li et al., 2009; Shi et al., 2007). This indicates that EZH2 function
(and perhaps other PRC2 components) can be uncoupled from
PRC2 enzymatic activities, and can act as a transcriptional switch
under certain conditions. These studies highlight the need for a
re-examination of the subcellular localization of PRC2 compo-
nents, and for a proper dissection of its functional activities
during the progression from proliferation to differentiation.
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